This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.
Valid: October 18th, 2011 - October 18th, 2012
The educational design of this activity addresses the needs of physicians, nurses, and pharmacists involved in the treatment of patients with diffuse large B-cell lymphoma (DLBCL).
Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with DLBCL.
After completing this activity, the participant should be better able to:
- Identify clinical and molecular markers of prognosis in patients with diffuse large B-cell lymphoma
- Describe recent safety and efficacy data from clinical trials investigating novel agents for the treatment of diffuse large B-cell lymphoma
- Select individualized management approaches for patients with relapsed or refractory diffuse large B-cell lymphoma
- Cite effective prophylactic measures and symptom monitoring for diffuse large B-cell lymphoma patients receiving targeted therapies, based on anticipated toxicities
Agenda - 1.25 hours
- Articles/Commentaries: 60 minutes
- Evaluation/Post-Test: 15 minutes
Physician Continuing Education Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group (Global) and Medical Learning Institute, Inc. (MLI). Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider 15106, for 1.25 contact hours.
Registered Pharmacy Designation
MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.25 contact hours (0.125 CEUs) of continuing education credit. The universal activity number for this activity is 0468-9999-11-079-H01-P.
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
*Stephanie A. Gregory, MD is on advisory boards for Amgen, Genentech, and Novartis. She has received research support from Astellas, Celgene, Cephalon, Genentech, GlaxoSmithKline, Immunomedics, NCIC CTG, Novartis, and Onyx.
*Susanne Liewer, PharmD, BCOP, has nothing to disclose.
Colleen Ross, RN, MSN, MHA, OCN, has nothing to disclose.
Julie M. Vose, MD, MBA, has received research grant support from Allos Therapeutics, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Incyte Corporation, Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals, Pharmacyclics, S*BIO Pte Ltd., sanofi-aventis, and US Biotest.
*Content will include non-FDA-approved uses.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Name of Planner
|Dana Delibovi||COEXM||Nothing to disclose|
|Jackie Dawson, MSN||Global||Nothing to disclose|
|Amanda Glazar, PhD||Global||Nothing to disclose|
|Shelley Chun, PharmD||MLI||Nothing to disclose|
|Kathryn Gada, MSN||MLI||Nothing to disclose|
The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.